Raymond James Financial
LENZ

Raymond James Financial’s LENZ Therapeutics LENZ Stock Holding History

Raymond James Financial’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,008
Closed -$137K – 5604
2026
Q1 		$137K Buy
15,008
+805
+6% +$11.3K ﹤0.01% 4967
2025
Q4 		$227K Buy
14,203
+2,993
+27% +$87.2K ﹤0.01% 4730
2025
Q3 		$522K Buy
11,210
+1,649
+17% +$60.6K ﹤0.01% 4099
2025
Q2 		$280K Hold
9,561
– – ﹤0.01% 4329
2025
Q1 		$246K Buy
9,561
+1,076
+13% +$26.5K ﹤0.01% 4319
2024
Q4 		$245K Buy
+8,485
New +$259K ﹤0.01% 4298

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Raymond James Financial's LENZ Position: Q2 2026 in Review

Raymond James Financial sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 15,008 shares — an estimated $137K sold.

Raymond James Financial first reported a position in LENZ in Q4 2024 and held it in 6 quarters. The position peaked at $522K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Raymond James Financial reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 15,008 LENZ Therapeutics shares in Q2 2026, an estimated $137K.
  • Raymond James Financial first reported a position in LENZ Therapeutics in Q4 2024 and held it in 6 quarters.
  • Raymond James Financial's LENZ Therapeutics position peaked at $522K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.